You are here:
Acitretin and teratogenicity: Compliance with safety measures in women of childbearing potential
2015.11.19
Active substance: acitretin
On a European level it is currently being discussed that the 2-year period of pregnancy prevention in patients of childbearing potential is possibly not sufficient and must therefore be extended to 3 years after end of treatment.
To the risk information - full text (available in German only)